Loading…
Radiopharm Theranostics Limited is projected to rise to $5.23 by 2027, a +15% move from its current price of $4.54. RADX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.43 | $4.54 | $4.66 | +0.04% |
| May 30 | $4.38 | $4.54 | $4.71 | +0.08% |
| May 31 | $4.35 | $4.55 | $4.75 | +0.12% |
| Jun 1 | $4.32 | $4.55 | $4.79 | +0.16% |
| Jun 2 | $4.29 | $4.55 | $4.82 | +0.20% |
| Jun 3 | $4.27 | $4.55 | $4.85 | +0.24% |
| Jun 4 | $4.25 | $4.55 | $4.87 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.25 | $4.55 | $4.87 | +0.28% |
| Week 2 | $4.15 | $4.57 | $5.03 | +0.55% |
| Week 3 | $4.07 | $4.58 | $5.15 | +0.83% |
| Week 4 | $4.01 | $4.59 | $5.26 | +1.11% |
| Week 5 | $3.95 | $4.60 | $5.36 | +1.38% |
| Week 6 | $3.91 | $4.62 | $5.45 | +1.66% |
| Week 7 | $3.87 | $4.63 | $5.54 | +1.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company that engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-MAb HER-2 breast diagnostic; RAD202, a Nano-MAb HER-2 breast therapeutic; RAD203, a Nano-MAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-MAb PDL1 non-small cell lung therapeutic.
Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.
The company was incorporated in 2021 and is based in Carlton, Australia.
RADX is the asset with current price $4.63 and market visibility through a market cap of $36.5M, ranking 4730. The forecast framework shows upside across 2026–2050, with the 2050 profile featuring an average of $24.70 and a maximum of $45.65.
In the near term, the forecast implies a gradual path of price increases from the 2026 baseline. For example, 2026’s average is $4.63, while later years project higher averages such as 2027 $5.38, 2028 $6.51, and 2029 $7.20, indicating the potential for meaningful upside over time.
Overall, the outlook combines a current price around $4.63 with a multi-year forecast that envisions rising averages and bullish sentiment in the longer horizon, anchored by the 2050 projection of $24.70 (avg) and $45.65 (max).
A major floor 19.5% below — a decisive break under it would weaken the trend.
The nearest floor, 11.9% below — buyers have tended to step in here.
The nearest ceiling, 5.5% above — a clean break opens room to run.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key RADX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RADX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.59 | Sell | $4.59 | Sell |
| MA 10 | $4.63 | Sell | $4.56 | Sell |
| MA 20 | $4.45 | Buy | $4.52 | Buy |
| MA 50 | $4.49 | Buy | $4.56 | Sell |
| MA 100 | $4.74 | Sell | $4.72 | Sell |
| MA 200 | $5.14 | Sell | $5.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.79 | Neutral |
| Stoch RSI (14) | 66.64 | Neutral |
| CCI (20) | 30.08 | Neutral |
| Williams %R (14) | -28.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 13.50 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 72.00 | Neutral |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 38.96 | Neutral |
| Momentum (10) | 0.38 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 4.57 | Sell |
| ADX (14) | 11.20 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is labeled as BULLISH in sentiment. The RSI(14) is 50, indicating a neutral-to-midable posture near the midpoint.
The stock trades near the SMA50 of $4.50 and below the SMA200 of $5.14, suggesting modest near-term upside potential depending on market dynamics. Support is at $4.00 and resistance at $4.79, with a thirty-day price range of $3.87 to $5.54.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.00 | $4.54 | $6.19 | 0% | Neutral | |
| $4.17 | $5.23 | $6.93 | +15% | Neutral | |
| $4.89 | $6.28 | $8.61 | +38% | Bullish | |
| $5.25 | $6.89 | $9.71 | +52% | Bullish | |
| $5.19 | $6.95 | $10.01 | +53% | Bullish | |
| $5.18 | $7.06 | $10.37 | +55% | Bullish | |
| $5.09 | $7.04 | $10.54 | +55% | Bullish | |
| $5.36 | $7.53 | $11.46 | +66% | Bullish | |
| $5.63 | $8.02 | $12.39 | +77% | Bullish | |
| $6.19 | $8.94 | $13.99 | +97% | Bullish | |
| $7.01 | $10.76 | $17.87 | +137% | Bullish | |
| $13.71 | $23.41 | $42.35 | +416% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.00 | $4.54 | $5.35 | +0.00% |
| June 2026 | $4.03 | $4.73 | $5.67 | +4.11% |
| July 2026 | $3.98 | $4.71 | $5.72 | -0.44% |
| August 2026 | $3.98 | $4.74 | $5.81 | +0.70% |
| September 2026 | $4.14 | $4.95 | $6.12 | +4.43% |
| October 2026 | $4.17 | $5.01 | $6.24 | +1.18% |
| November 2026 | $4.04 | $4.88 | $6.11 | -2.61% |
| December 2026 | $4.05 | $4.91 | $6.19 | +0.62% |
Click any year to see its month-by-month RADX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RADX could reach as high as $6.19, with a base case around $4.54 and support toward $4.00 — roughly 0% from $4.54. Price action looks broadly range-bound.
Expect RADX to range from $4.17 to $6.93 through 2027. The $5.23 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RADX price prediction for 2028 points to an average of $6.28 (low $4.89, high $8.61) — a potential gain of +38% on today's $4.54. Momentum favours further upside here.
In 2029, RADX is projected to trade between $5.25 and $9.71, averaging $6.89 — a potential gain of +52% from today's $4.54. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Radiopharm Theranostics Limited's 2030 outlook centres on $6.95, within a $5.19 to $10.01 range. That is up +1% on the projected 2029 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2031, RADX could reach as high as $10.37, with a base case around $7.06 and support toward $5.18 — roughly +55% from $4.54. Buyers look set to stay in control over this stretch.
Expect RADX to range from $5.09 to $10.54 through 2032. The $7.04 average target implies a +55% move from current prices. That is 0% versus the projected 2031 average. Momentum favours further upside here.
The RADX price prediction for 2033 points to an average of $7.53 (low $5.36, high $11.46) — a potential gain of +66% on today's $4.54. Buyers look set to stay in control over this stretch.
In 2034, RADX is projected to trade between $5.63 and $12.39, averaging $8.02 — a potential gain of +77% from today's $4.54. That is up +7% on the projected 2033 average. Momentum favours further upside here.
Radiopharm Theranostics Limited's 2035 outlook centres on $8.94, within a $6.19 to $13.99 range. That is up +11% on the projected 2034 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RADX could reach as high as $17.87, with a base case around $10.76 and support toward $7.01 — roughly +137% from $4.54. Momentum favours further upside here.
Expect RADX to range from $13.71 to $42.35 through 2050. The $23.41 average target implies a +416% move from current prices. That is up +117% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RADX today (≈ 220.264317 RADX) could be worth
$5,155.69
+$4,155.69 (+416%) by 2050 · US Dollar
Based on the average projected RADX price of $23.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RADXwould be worth at today's price.
$1,000 invested in RADX on May 27, 2025 (≈ 206.185571 RADX) would be worth
$936.08
-$63.92 (-6.4%) today · 0.94× · US Dollar
Based on a RADX entry price of $4.85 vs. today's $4.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.58 | $991.27 | -0.9% |
| 1 month ago | $4.65 | $976.34 | -2.4% |
| 3 months ago | $4.98 | $911.65 | -8.8% |
| 6 months ago | $4.56 | $995.61 | -0.4% |
| 1 year ago | $4.85 | $936.08 | -6.4% |
| All time (1.5y) ago | $17.67 | $256.93 | -74.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RADX forecast.
Our base-case forecast reaches $9.10 around 2040.
Implied market cap at $9.10: $71.74M
2026 forecast shows min $4.00, avg $4.63, max $6.41, ROI 0, sentiment NEUTRAL. The 2027 forecast shows min $4.27, avg $5.38, max $7.19, ROI 16.3, sentiment NEUTRAL. The 2028 forecast shows min $5.02, avg $6.51, max $9.01, ROI 40.6, sentiment BULLISH. The 2029 forecast shows min $5.44, avg $7.20, max $10.25, ROI 55.6, sentiment BULLISH.
The 2030 forecast shows min $5.31, avg $7.18, max $10.46, ROI 55, sentiment BULLISH. The 2031 forecast shows min $5.29, avg $7.29, max $10.84, ROI 57.4, sentiment BULLISH. The 2032 forecast shows min $5.24, avg $7.34, max $11.13, ROI 58.5, sentiment BULLISH.
The 2033 forecast shows min $5.46, avg $7.77, max $11.98, ROI 67.7, sentiment BULLISH. The 2034 forecast shows min $5.74, avg $8.30, max $13.01, ROI 79.3, sentiment BULLISH. The 2035 forecast shows min $6.40, avg $9.38, max $14.92, ROI 102.7, sentiment BULLISH.
The 2040 forecast shows min $7.12, avg $11.15, max $18.85, ROI 140.9, sentiment BULLISH. The 2050 forecast shows min $14.06, avg $24.70, max $45.65, ROI 433.5, sentiment BULLISH.
Tap a question to reveal the answer.
2030: min $5.31, avg $7.18, max $10.46, ROI 55%, sentiment BULLISH.
Forecasts show a path of rising averages through 2027–2050, with 2030 avg $7.18, 2040 avg $11.15, and 2050 avg $24.70. ROI reaches 55% in 2030, 140.9% in 2040, and 433.5% in 2050, with sentiment BULLISH in later years.
2040 max is $18.85, while 2050 max is $45.65, so reaching $20 would not occur by 2040 but is possible by 2050 given the forecast.
Current price is $4.63 and market cap is $36.5M.
The 30-day range is $3.87 to $5.54.
Radiopharm Theranostics Limited Community Discussion
0Share your Radiopharm Theranostics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.